CTCFL and ovarian cancer: Aberrant expression of BORIS has been reported in various primary cancers including glioblasma [41], melanomas [42], head and neck squamous cell carcinoma [43], esophageal cancer [37], breast cancer [44, 45], prostate cancer [46], uterine corpus cancer [47, 48] and ovarian cancer [49] at mRNA or protein levels.